Abstract 316P
Background
Although Olaparib has demonstrated substantial clinical benefits as maintenance therapy in BRCA mutation-carrying women with newly diagnosed advanced ovarian cancer, its effectiveness in patients without BRCA mutations remains under-investigated. This study aims to provide the first evidence on the efficacy of olaparib maintenance therapy in such a context.
Methods
Using real-world data from eleven high-volume tertiary care centers in China, we conducted a retrospective cohort study to assess the efficacy and safety of olaparib maintenance therapy in BRCA wild-type ovarian cancer patients in the first-line setting. Eligible women were identified by medical record review at each institution. The primary objective was the 1-year progression-free survival (PFS) rate. Details of safety profile were also evaluated.
Results
A total of 50 patients with a median age of 54 years were included. Of these patients, 44 (88%) had International Federation of Gynaecology and Obstetrics (FIGO) stage III disease at diagnosis, while 6 (12%) had stage IV disease. The 1-year PFS rate was 75.2% (95% CI, 63.4 to 89.2) and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). All patients received olaparib at a starting dose of 300 mg twice daily and no patients experienced serious adverse events (AEs). Eight (16%) patients had a dose adjustment, but no patients discontinued olaparib treatment due to AEs.
Conclusions
We provide the first evidence that olaparib could be a safe and effective first-line maintenance treatment for women with BRCA wild-type ovarian cancer. These findings propose a new treatment option for this sizable patient subgroup.
Clinical trial identification
NCT05153603.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AZ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract